Profile data is unavailable for this security.
About the company
Humanwell Healthcare Group Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceuticals. The Company primarily operates its businesses through two segments. Pharmaceutical segment is mainly engaged in the research and development, production and sales of pharmaceutical products and the research and development, production and sales of medical device products, as well as the delivery, distribution and related businesses of pharmaceutical products, providing drugs, devices, medical equipment, reagents, consumables, health products, as well as technology and management services. The Company's products include chemical pharmaceutical preparations, chemical active pharmaceutical ingredients and others. Environmental Protection segment is primarily engaged in environmental protection engineering business.
- Revenue in CNY (TTM)24.67bn
- Net income in CNY1.96bn
- Incorporated1993
- Employees17.68k
- LocationHumanwell Healthcare Group Co LtdNo. 666 Gaoxin AvenueDonghu High-Tech DistrictWUHAN 430075ChinaCHN
- Phone+86 2 787597232
- Fax+86 2 787596393
- Websitehttp://www.humanwell.com.cn
More ▼
Mergers & acquisitions
| Acquired company | 600079:SHH since announced | Transaction value |
|---|---|---|
| PAION AG | -33.41% | -- |
Data delayed at least 15 minutes, as of Jul 05 2024.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhejiang Huahai Pharmaceutical Co., Ltd. | 8.75bn | 928.37m | 23.72bn | 8.22k | 25.30 | 2.81 | -- | 2.71 | 0.6391 | 0.6391 | 6.02 | 5.76 | 0.4511 | 1.08 | 3.46 | 1,064,162.00 | 4.76 | 5.67 | 6.90 | 8.07 | 59.44 | 60.52 | 10.55 | 11.61 | 0.8451 | 5.48 | 0.5047 | 33.55 | 0.5199 | 10.28 | -28.88 | 50.51 | 7.21 | -- |
| Shanghai Junshi Biosciences Co Ltd | 1.63bn | -2.02bn | 23.82bn | 2.57k | -- | 4.01 | -- | 14.63 | -2.06 | -2.06 | 1.66 | 6.97 | 0.1348 | 1.05 | 4.11 | 634,034.10 | -18.18 | -18.87 | -23.17 | -23.11 | 64.05 | 69.13 | -134.86 | -88.41 | 1.91 | -215.80 | 0.3018 | -- | 3.38 | 248.39 | 4.38 | -- | 8.36 | -- |
| Gan & Lee Pharmaceuticals | 2.61bn | 386.85m | 25.37bn | 4.48k | 62.84 | 2.30 | -- | 9.72 | 0.6716 | 0.6716 | 4.52 | 18.38 | 0.234 | 0.8926 | 10.97 | 582,412.30 | 3.47 | 8.30 | 3.71 | 8.83 | 72.29 | 85.39 | 14.83 | 26.44 | 7.74 | -- | 0.0006 | 13.65 | 52.31 | 1.78 | 177.37 | -18.30 | 1.50 | -- |
| Bluestar Adisseo Co | 13.53bn | 327.58m | 25.67bn | 2.73k | 78.35 | 1.70 | -- | 1.90 | 0.1222 | 0.1222 | 5.04 | 5.63 | 0.6286 | 4.67 | 7.33 | 4,947,799.00 | 1.52 | 5.28 | 1.85 | 6.94 | 23.81 | 30.31 | 2.42 | 8.76 | 1.04 | 4.30 | 0.1325 | 21.81 | -9.26 | 2.92 | -95.82 | -43.75 | 2.74 | -19.09 |
| Humanwell Healthcare Group Co Ltd | 24.67bn | 1.96bn | 26.03bn | 17.68k | 13.22 | 1.49 | -- | 1.06 | 1.21 | 1.21 | 15.25 | 10.73 | 0.6833 | 3.80 | 2.77 | 1,395,473.00 | 7.21 | 6.20 | 13.29 | 12.72 | 45.02 | 42.82 | 10.55 | 9.84 | 1.20 | 31.56 | 0.3293 | 18.87 | 9.79 | 5.65 | -14.07 | -- | 8.25 | -- |
| Kangmei Pharmaceutical Co Ltd | 4.93bn | 160.40m | 29.39bn | 4.41k | 182.29 | 4.14 | -- | 5.96 | 0.0116 | 0.0116 | 0.3577 | 0.5117 | 0.34 | 1.40 | 2.43 | 1,118,464.00 | 1.12 | -17.60 | 1.69 | -32.24 | 22.71 | -72.78 | 3.28 | -101.19 | 0.8746 | -- | 0.0465 | -- | 16.60 | -22.17 | 103.81 | -22.83 | -53.51 | -- |
| Hubei Jumpcan Pharmaceutical Co Ltd | 9.67bn | 2.99bn | 29.73bn | 5.23k | 9.89 | 2.08 | -- | 3.07 | 3.26 | 3.26 | 10.54 | 15.51 | 0.5504 | 3.66 | 4.60 | 1,848,716.00 | 17.05 | 16.23 | 22.52 | 20.88 | 79.76 | 82.64 | 30.98 | 24.42 | 3.01 | -- | 0.1275 | 41.76 | 7.32 | 6.02 | 30.04 | 10.83 | -14.70 | 1.11 |
Data as of Jul 05 2024. Currency figures normalised to Humanwell Healthcare Group Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
19.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Harvest Fund Management Co., Ltd.as of 31 Dec 2023 | 50.59m | 3.47% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 44.75m | 3.07% |
| China Merchants Fund Management Co., Ltd.as of 30 Sep 2023 | 39.69m | 2.72% |
| Bank of Communications Schroder Fund Management Co., Ltd.as of 31 Dec 2023 | 30.89m | 2.12% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 23.73m | 1.63% |
| Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 31 Dec 2023 | 22.17m | 1.52% |
| Zhong Ou Asset Management Co., Ltdas of 30 Sep 2023 | 19.03m | 1.31% |
| JPMorgan Asset Management (China) Co Ltd.as of 31 Dec 2023 | 18.45m | 1.27% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 16.20m | 1.11% |
| GF Fund Management Co., Ltd.as of 30 Sep 2023 | 12.83m | 0.88% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
